beta-lactams has been researched along with Gasser Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adak, GK; Byrne, L; Charlett, A; Harker, K; Jenkins, C; Launders, N | 1 |
| Bender, JB; Hedberg, CW; Hedican, EB; Reiter, PL; Smith, KE; Wilker, PR | 1 |
2 other study(ies) available for beta-lactams and Gasser Syndrome
| Article | Year |
|---|---|
Disease severity of Shiga toxin-producing E. coli O157 and factors influencing the development of typical haemolytic uraemic syndrome: a retrospective cohort study, 2009-2012.
Topics: Adolescent; Adult; Age of Onset; Aged; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Disease Progression; England; Escherichia coli Infections; Female; Hemolytic-Uremic Syndrome; Humans; Incidence; Infant; Male; Middle Aged; Population Surveillance; Retrospective Studies; Risk Factors; Severity of Illness Index; Shiga-Toxigenic Escherichia coli; Young Adult | 2016 |
Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Case-Control Studies; Child; Child, Preschool; Escherichia coli Infections; Escherichia coli O157; Female; Hemolytic-Uremic Syndrome; Humans; Infant; Infant, Newborn; Male; Minnesota; Risk Factors; Severity of Illness Index; Young Adult | 2012 |